Latest Ipilimumab Stories

2011-03-25 11:23:00

Melanoma patients lived longer with treatment SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.

2010-12-09 17:22:28

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone.

2010-09-09 11:34:00


2010-08-26 14:03:25

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

2010-08-26 14:00:17

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas.

2009-09-23 08:15:00

Researchers have made significant advances in the treatment of metastatic malignant melanoma – one of the most difficult cancers to treat successfully once it has started to spread – according to a study to be presented at Europe's largest cancer congress, ECCO 15 – ESMO 34 [1], in Berlin on Thursday.

2009-08-12 08:18:01

Patients with stage III or IV melanoma taking ipilimumab and the oral steroid budesonide to reduce side effects did not have less diarrhea, a known side effect of ipilimumab, according to results of a phase II trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

2009-08-03 11:06:00

SAN FRANCISCO, Aug. 3 /PRNewswire/ -- Biotech was "hot" in July driven by drug data, positive drug sales/earnings and partnering and M&A deals.

Word of the Day
  • Large; stout; burly.
The word 'bowerly' is an alteration of 'burly'.